Project Grant R41AR087264
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $314K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newtonville, MA 02458, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Johns Hopkins University $187,172 on July 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to conduct a prospective, multi-center observational study validating biochemical and imaging biomarkers as predictors of incident fracture in Duchenne muscular dystrophy. The study will enroll 150 people with DMD over two years and operate across three leading...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ikaika Therapeutics Inc. $995,938 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund preclinical development of anti-LTBP4 monoclonal antibodies for treating neuromuscular diseases. The project develops second-generation anti-LTBP4 antibodies targeting the hinge region of latent TGF-binding protein 4, which regulates pathological TGF-β activation...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health under the Department of Health and Human Services, awarded $585,012 to Massachusetts General Hospital on June 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research investigating the role of the C10ORF10/DEPP1 protein in skeletal muscle atrophy. The recipient will conduct three specific aims: defining the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $1.696 million to Poly Orth International on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds translational pre-clinical research and development of a 3D-printed skin and bone integrated pylon (SBIP-3D) for direct skeletal attachment of limb prostheses. The technology, developed by Poly Orth International, integrates with both residual bone...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Carnegie Mellon University $1.04 million on April 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate a sensorized compression sleeve for muscle-activity monitoring and rehabilitation tracking in patients following anterior cruciate ligament reconstruction. The research investigates capacitive sensing embedded in e-textiles as a tool to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $151,040 to The University of Texas Southwestern Medical Center on April 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop muscle-optimized non-viral gene editors for Duchenne muscular dystrophy. The project addresses limitations in lipid nanoparticle (LNP) delivery of CRISPR gene editing to skeletal muscle by designing gene editors that improve myonuclear...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Boston Children's Hospital a $177,000 Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) on August 20, 2025, with completion anticipated by July 31, 2027. The project delivers research services focused on identifying novel modulators of limb development and chondrocyte maturation through genome-wide functional screening. The research team will...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Florida $1.768 million on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to assess magnetic resonance measures of bioenergetics and microvascular function in Duchenne and Becker muscular dystrophy. The project evaluates whether MR-based measures of muscle energetics and blood vessel function can track disease progression and treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $377,506 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a chimeric antigen receptor T cell (CAR-T) therapy targeting inflammation and fibrosis in Duchenne muscular dystrophy. The research will evaluate CAR-T cells engineered to eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors in the dystrophic muscle...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the Board of Trustees of Illinois State University $544,734 on August 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate smooth muscle pathology mechanisms in Duchenne muscular dystrophy. The project, running through July 31, 2029, uses C. elegans as a model system to characterize smooth muscle dysfunction associated with...